INMB
Inmune Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.54
−1.91%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +53.4%
- EBIT
- +64.1%
- EPS
- +72.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +91.4%
- EPS
- -30.9%
Three-year CAGR
- Revenue
- -48.9%
- EBITDA
- -10.4%
- EBIT
- +27.6%
- Net income
- -9.2%
- EPS
- +11.8%
- Free cash flow
- +29.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026